

| | | |
|---|--------------------------------|----------------------------------|
| FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary) | Docket Number: 11757.79USWO | Application Number: 10/526111 |
| | Applicant: YOUSEF | |
| | Filing Date: Herewith | Group Art Unit: Unknown |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|--------------|------|------|-------|----------|----------------------------|
| EXAMINER INITIAL | DOCUMENT NO. | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |


| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--------------|-----------------|---------|-------|----------|-------------|----|
| | DOCUMENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | YES | NO |
| AMG | 00/53776 | September, 2000 | WIPO | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|--|--|---|
| AMG | | Diamandis, et al., "The New Human Kallikrein Gene Family: Implications in Carcinogenesis", TEM vol. 11, no. 2, 2000, 54-60 |
| AMG | | Kapadia, et al., "Human Kallikrein 13: Production and Purification of Recombinant Protein and Monoclonal and Polyclonal Antibodies, and Development of a Sensitive and Specific Immunofluorometric Assay", Clinical Chemistry 49:1, 77-86, 2003 |
| AMG | | Yousef, et al., "Identification and Characterization of <i>KLK-L4</i> , a New Kallikrein-like Gene that Appears to be Down-regulated in Breast Cancer Tissues", The Journal of Biological Chemistry, vol. 275, no. 16, Issue of April 21, pp. 11891-11898, 2000 |
| | | |

23552

PATENT TRADEMARK OFFICE

| | | | |
|---|---------------|-----------------|------------|
| EXAMINER | /Anne Gussow/ | DATE CONSIDERED | 02/26/2007 |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | | | |



| | | | | | | |
|---|---|----|---|--------------------------|-------------------|-----------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | | |
| | | | | Application Number | 10/526,111 | |
| | | | | Filing Date | November 22, 2005 | |
| | | | | First Named Inventor | Yousef et al. | |
| | | | | Art Unit | 1643 | |
| | | | | Examiner Name | A. Gussow | |
| Sheet | 1 | of | 9 | Attorney Docket Number | | MTS13AUSA |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| AMG | AA | US-2006-0134114 | 06-22-2006 | Diamandis | |
| ↓ | AB | US-2006-0073525 | 04-06-2006 | Yousef. | |
| | AC | US-2004-0058342 | 03-25-2004 | Yousef et al. | |
| | AD | US-2004-0096915 | 05-20-2004 | Diamandis | |
| | AE | US-2006-0223059 | 10-05-2006 | Yousef | |
| | AF | US-2006-0269971 | 11-30-2006 | Diamandis | |
| ↓ | AG | US-2005-0106586 | 05-19-2005 | Diamandis | |
| | AH | US-2006-0141471 | 06-29-2006 | Diamandis | |
| AMG | AI | US-2006-0134120 | 06-22-2006 | Diamandis | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ -Kind Code ⁵ (if known) | | | | |
| AMG | AL | WO-2000/053776 | 09-14-2000 | Yousef et al. | | |
| ↓ | AM | WO-2002/014485 | 02-02-2002 | Yousef et al. | | |
| | AN | WO-2002/037112 | 05-10-2002 | Diamandis et al. | | |
| | AO | WO-2002/035232 | 05-02-2002 | Diamandis | | |
| ↓ | AP | WO-2002/097438 | 12-05-2002 | Diamandis | | |
| | AQ | WO-2003/033731 | 04-24-2003 | Diamandis et al. | | |
| AMG | AAL | WO-2003/085404 | 10-16-2003 | Diamandis et al. | | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Anne Gussow/ | Date Considered | 02/26/2007 |
|--------------------|---------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | | |
|--|-----------|----|---|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/526,111 |
| | | | | Filing Date | November 22, 2005 |
| | | | | First Named Inventor | Yousef et al. |
| | | | | Art Unit | 1643 |
| Examiner Name | A. Gussow | | | | |
| Sheet | 2 | of | 9 | Attorney Docket Number | MTS13AUSA |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| AMG | AJ | US-2004-0115745 | 06-17-2004 | Diamandis | |
| ↓ | AK | US-2005-0287528 | 12-29-2005 | Diamandis | |
| | AAA | US-2005-0176002 | 08-11-2005 | Diamandis | |
| | AAB | US-2004-0203012 | 10-14-2004 | Diamandis | |
| | AAC | US-7,022,497 | 04-04-2006 | Yousef et al. | |
| ↓ | AAD | US-6,962,793 | 11-08-2005 | Diamandis | |
| | AAE | US-2003-0108963 | 06-12-2003 | Schlegel et al. | |
| AMG | AAF | US-2006-0172608 | 08-03-2006 | Yousef et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|--|--------------------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ -Kind Code ⁵ (if known) | | | | |
| AMG | AAM | WO-2004/021008 | 03-11-2004 | Diamandis | | |
| ↓ | AAN | WO-2004/029285 | 04-08-2004 | Yousef et al. | | |
| | AAO | WO-2004/029616 | 04-08-2004 | Diamandis | | |
| ↓ | AAP | WO-2004/075713 | 09-10-2004 | Diamandis | | |
| AMG | AAQ | WO-2004/077060 | 09-10-2004 | Diamandis et al. | | |

| | | | |
|-----------------------|---------------|--------------------|------------|
| Examiner Signature | /Anne Gussow/ | Date Considered | 02/26/2007 |
|-----------------------|---------------|--------------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | | |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/526,111 |
| | | | | Filing Date | November 22, 2005 |
| | | | | First Named Inventor | Yousef et al. |
| | | | | Art Unit | 1643 |
| | | | | Examiner Name | A. Gussow |
| Sheet | 3 | of | 9 | Attorney Docket Number | MTS13AUSA |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| AMG | AR | AIMES et al., "Endothelial Cell Serine Proteases Expressed During Vascular Morphogenesis and Angiogenesis", Throm. Haemost. 89(3):561-572 (March, 2003) (Abstract) | |
| | AS | AUERSPERG et al., "The Biology of Ovarian Cancer", Semin. Oncol., 25(3):281-304 (June, 1998) (Abstract) | |
| | AT | BALBAY et al., "Highly Metastatic Human Prostate Cancer Growing within the Prostate of Athymic Mice Overexpresses Vascular Endothelial Growth Factor", Clin. Cancer Res., 5:783-789 (April, 1999) | |
| | AU | BHoola et al., "Bioregulation of Kinins: Kallikreins, Kininogens, and Kininases", Pharm. Rev., 44(1):1-80 (March, 1992) | |
| | AV | BORGONO et al., "Favorable Prognostic Value of Tissue Human Kallikrein 11 (hK11) in Patients with Ovarian Carcinoma", Int. J. Cancer, 106:605-610 (September 10, 2003) | |
| | AW | CARDILLO et al., "Androgen Receptors in Ovarian Tumors: Correlation with Oestrogen and Progesterone Receptors in an Immunohistochemical and Semiquantitative Image Analysis Study", J. Exp. Clin. Cancer Res., 18(2):231-237 (June, 1998) (Abstract) | |
| | AX | CHANG et al., "Identification and Molecular Characterization of Five Novel Kallikrein Gene 13 (KLK13; KLK-L4) Splice Variants: Differential Expression in the Human Testis and Testicular Cancer", Anticancer Res., 21(5):3147-3152 (September-October, 2001) (Abstract) | |
| | AY | CHEN et al., "Prostasin Serine Protease Inhibits Breast Cancer Invasiveness and is Transcriptionally Regulated by Promoter DNA Methylation", Int. J. Cancer, 97:323-329 (January 20, 2002) | |
| | AZ | CHEN et al., "Down-Regulation of Prostasin Serine Protease: A Potential Invasion Suppressor in Prostate Cancer", The Prostate, 48:93-103 (July 1, 2001) | |
| | AAR | CHRISTOPOULOS et al., "Enzymatically Amplified Time-Resolved Fluorescence Immunoassay with Terbium Chelates", Anal. Chem., 64(4): 342 (February 15, 1992) | |
| | AAS | DAY et al., "Epithelial Carcinoma of the Ovary: Prognostic Importance of Histologic Grade", Natl. Cancer Inst. Monogr. 42:15-21 (October, 1975) | |
| | AAT | DECLERCK et al., "Proteases and Protease Inhibitors in Tumor Progression", Adv. Exp. Med. Biol., 425:89-97 (1997) (Abstract) | |
| | AAU | DEL ROSSO et al., "Multiple Pathways of Cell Invasion are Regulated by Multiple Families of Serine Proteases", Clin. & Exp. Metastasis, 19:193-207 (2002) | |
| AMG | AAV | DEPERTHEs et al., "Isolation of Prostatic Kallikrein hK2, Also Known as hGK-1, in Human Seminal Plasma", Biochemica et Biophysica Acta, 1245:311-316 (December 14, 1995) | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Anne Gussow/ | Date Considered | 03/07/2007 |
|--------------------|---------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/526,111 |
| | | | | Filing Date | November 22, 2005 |
| | | | | First Named Inventor | Yousef et al. |
| | | | | Art Unit | 1643 |
| | | | | Examiner Name | A. Gussow |
| Sheet | 4 | of | 9 | Attorney Docket Number | MTS13AUSA |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| AMG | AAW | DIAMANDIS et al., "Human Kallikrein 11: A New Biomarker of Prostate and Ovarian Carcinoma", Cancer Res., 62:295-300 (January 1, 2002) | |
| | AAX | DIAMANDIS et al., "Immunofluorometric assay of Human Kallikrein 6 (Zyme/Protease M/Neurosin) and Preliminary Clinical Applications", Clin. Biochem., 33(5):369-375 (July, 2000) | |
| | AAY | DIAMANDIS et al., "Human Kallikrein 6 (Zyme/Protease M/Neurosin): A New Serum Biomarker of Ovarian Carcinoma", Clin. Biochem., 33(7):579-583 (October, 2000) | |
| | AAZ | DIAMANDIS et al., "Human Tissue Kallikreins: A Family of New Cancer Biomarkers", Clin. Chem., 48(8):1198-1205 (August, 2002) | |
| | BR | DIAMANDIS et al., "New Nomenclature for the Human Tissue Kallikrein Gene Family", Clin. Chem., 46(11):1855 (November 2000) | |
| | BS | DIAMANDIS et al., "Human Kallikrein 6 (nK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Cancer", J. Clin. Oncol., 21(6):1035-1043 (March 15, 2003) | |
| | BT | DONG et al., "Human Kallikrein 4 (KLK4) is Highly Expressed in Serous Ovarian Carcinomas", Clin. Cancer Res., 7:2363-2371 (August, 2001) | |
| | BU | DUFFY, "Proteases as Prognostic Markers in Cancer", Clin. Cancer Res., 2:613-618 (April, 1996) | |
| | BV | DUFFY, "The Role of Proteolytic Enzymes in Cancer Invasion and Metastasis", Clin. Exp. Metastasis, 10:145-155 (May, 1992) | |
| | BW | DUFFY et al., "Urokinase Plasminogen Activator: A Prognostic Marker in Multiple Types of Cancer", H. Surg. Oncol., 71:130-135 (June, 1999) | |
| | BX | EISENHAUER et al., "Ovarian Cancer: Should We Be Managing Patients with Good and Bad Prognostic Factors in the Same Manner", Annals of Oncol., 10(Suppl. 1):S9-S15 (1999) | |
| | BY | FOEKENS et al., "The Prognostic Value of Polymorphonuclear Leukocyte Elastase in Patients with Primary Breast Cancer", Cancer Res., 63:337-341 (January 15, 2003) | |
| | BZ | GOTLIEB et al., "Topoisomerase II Immunostaining as a Prognostic Marker for Survival in Ovarian Cancer", Gynecologic Oncology, 82:99-104 (May 31, 2001) | |
| ✓ | BBR | GOYAL et al., "The Role for NES1 Serine Protease as a Novel Tumor Suppressor", Cancer Res., 58:4782-4786 (November 1, 1998) | |
| AMG | BBS | GRAUER et al., "Identification of Human Glandular Kallikrein hK2 from LNCaP Cells", J. Andrology, 17(4):353 (July/August 1996) | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Anne Gussow/ | Date Considered | 03/07/2007 |
|--------------------|---------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | | | | | |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/526,111 |
| | | | | Filing Date | November 22, 2005 |
| | | | | First Named Inventor | Yousef et al. |
| | | | | Art Unit | 1643 |
| Sheet | 5 | of | 9 | Examiner Name | A. Gussow |
| | | | | Attorney Docket Number | MTS13AUSA |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| AMG | BBT | GRAUER et al., "Detection of Human Glandular Kallikrein, hK2, as Its Precursor Form and in Complex with Protease Inhibitors in Prostate Carcinoma Serum", J. Andrology, 19(4):407-411 (July/August 1998) | |
| | BBU | HARBECK et al., "Prognostic Impact of Proteolytic Factors (Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor 1, and Cathepsins B, C, and L) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy", Clin. Cancer Res., 7:2757-2764 (September, 2001) | |
| | BBV | HATA et al., "Expression of the <i>Endostatin</i> Gene in Epithelial Ovarian Cancer", Clin. Cancer Res., 7:2405-2409 (August, 2001) | |
| | BBW | HAVIV et al. "DNA Microarrays for Assessing Ovarian Cancer Gene Expression", Mol. Cell., Endocrinol., 191:121-126 (May 31, 2002) | |
| | BBX | HENDERSON et al., "Hormonal Carcinogenesis", Carcinogenesis, 21(3):427-433 (March, 2000) | |
| | BBY | HOFFMAN et al., "Immunofluorometric Quantitation and Histochemical Localisation of Kallikrein 6 Protein in Ovarian Cancer Tissue: A New Independent Unfavorable Prognostic Biomarker", Brit. J. Cancer, 87:763-771 (September 23, 2002) | |
| | BBZ | HOOPER et al., "Identification and Characterization of KLK14, a Novel Kallikrein Serine Protease Gene Located on Human Chromosome 19q13.4 and Expressed in Prostate and Skeletal Muscle", Genomics, 73:117-122 (April 1, 2001) | |
| | CR | HOOPER et al., "Testisin, a New Human Serine Proteinase Expressed by Premeiotic Testicular Germ Cells and Lost in Testicular Germ Cell Tumors", Cancer Res., 59:3199-3205 (July 1, 1999) | |
| | CS | HOUGH et al., "Large-Scale Serial Analysis of Gene Expression Reveals Genes Differentially Expressed in Ovarian Cancer", Cancer Res., 60:6281-6287 (November 15, 2000) | |
| | CT | HSIA et al., "Prognostic Significance of Caspase-3 Expression in Primary Resected Esophageal Squamous Cell Carcinoma", Eur. J. Surg. Oncol., 29:44-48 (February, 2003) | |
| | CU | IMPOLA et al., "Matrix Metalloproteinase-19 is Expressed by Proliferating Epithelium but Disappears with Neoplastic Dedifferentiation", Int. J. Cancer., 103:709-716 (March 1, 2002) | |
| AMG | CV | ISOLA, "Immunohistochemical Demonstration of Androgen Receptor in Breast Cancer and its Relationship to Other Prognostic Factors", J. Pathol., 170:31-35 (May, 1993) | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Anne Gussow/ | Date Considered | 03/07/2007 |
|--------------------|---------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

| | | | | | |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/526,111 |
| | | | | Filing Date | November 22, 2005 |
| | | | | First Named Inventor | Yousef et al. |
| | | | | Art Unit | 1643 |
| | | | | Examiner Name | A. Gussow |
| Sheet | 6 | of | 9 | Attorney Docket Number | MTS13AUSA |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| AMG | CW | JUNG et al., "Ratio of Free or Complexed Prostate-Specific Antigen (PSA) to Total PSA: Which Ratio Improves Differentiation Between Benign Prostatic Hyperplasia and Prostate Cancer?", Clin. Chem., 46(1):55-62 (January, 2000) | |
| | CX | KIM et al., "Human Kallikrein Gene 5 (KLK5) Expression is an Indicator of Poor Prognosis in Ovarian Cancer", Br. J. Cancer, 84:643-650 (March 2, 2001) | |
| | CY | KONECNY et al., "Association of Urokinase-Type Plasminogen Activator and Its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer", Clin. Cancer Res., 7:1743-1749 (June, 2001) | |
| | CZ | KOS et al., "Cysteine Proteinases and Their Endogenous Inhibitors: Target Proteins for Prognosis, Diagnosis and Therapy in Cancer (Review)", Oncol. Rep., 5:1349-1371 (November-December, 1998) (Abstract) | |
| | CCR | KYRIAKOPOULOU et al., "Prognostic Value of Quantitatively Assessed KLK7 Expression in Ovarian Cancer", Clin. Biochem., 36:135-143 (March, 2003) | |
| | CCS | LENGYEL et al., "Expression of Latent Matrix Metalloproteinase 9 (MMP-9) Predicts Survival in Advanced Ovarian Cancer", Gynecol Oncol., 82:291-298 (June 22, 2001) | |
| | CCT | LIAO et al., "Roles of Androgens in the Development, Growth, and Carcinogenesis of the Mammary Gland", J. Steroid Biochem. Mol. Biol., 80:175-189 (February, 2002) | |
| | CCU | LILJA et al., "Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with α_1 -Antichymotrypsin", Clin. Chem., 37(9):1618-1625 (September, 1991) | |
| | CCV | LILJA et al., "Three Predominant Proteins Secreted by the Human Prostate Gland", The Prostate, 12:29-38 (1988) | |
| | CCW | LUO et al., "The Serum Concentration of Human Kallikrein 10 Represents a Novel Biomarker for Ovarian Cancer Diagnosis and Prognosis", Cancer Res., 63:807-811 (February 15, 2003) | |
| | CCX | LUO et al., "Prognostic Value of Human Kallikrein 10 Expression in Epithelial Ovarian Carcinoma", Clin. Cancer Res., 7:2372-2379 (August, 2001) | |
| | CCY | LUO et al., "Immunofluorometric Assay of Human Kallikrein 10 and Its Identification in Biological Fluids and Tissues", Clin. Chem., 46:237-246 (February, 2001) | |
| ↓ | CCZ | LUO et al., "Human Kallikrein 10: A Novel Tumor Marker for Ovarian Carcinoma?", Clin. Chim. Acta., 306:111-118 (April, 2001) | |
| AMG | DR | MAGKLARA et al., "The Human KLK8 (Neurosin/Ovasin) Gene: Identification of Two Novel Splice Variants and its Prognostic Value in Ovarian Cancer", Clin. Cancer Res., 7:806-811 (April, 2001) | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Anne Gussow/ | Date Considered | 03/07/2007 |
|--------------------|---------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 10/526,111 |
| | | Filing Date | November 22, 2005 |
| | | First Named Inventor | Yousef et al. |
| | | Art Unit | 1643 |
| Examiner Name | A. Gussow | | |
| Sheet 7 of 9 | Attorney Docket Number | | MTS13AUSA |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| AMG | DS | MASCIULLO et al., "p27 ^{KIP1} Expression Is Associated with Clinical Outcome in Advanced Epithelial Ovarian Cancer: Multivariate Analysis", Clin. Cancer Res., 6:4816-4822 (December, 2000) | |
| | DT | MCCORMACK et al., "Molecular Forms of Prostate-Specific Antigen and the Human Kallikrein Gene Family: A New Era", Urology, 45(5):729-744 (May, 1995) | |
| | DU | MIKOLAJCZYK et al., "Prostatic Human Kallikrein 2 Inactivates and Complexes with Plasminogen Activator Inhibitor-1", Int. J. Cancer, 81:439-442 (May 5, 1999) | |
| | DV | MILDE-LANGOSCH et al., "Expression and Prognostic Value of the Cell-Cycle Regulatory Proteins, Rb, p16 ^{MTS1} , p21 ^{WAF1} , p27 ^{KIP1} , Cyclin E, and Cyclin D2 in Ovarian Cancer", Int. J. Gynecol. Pathol., 22:168-174 (April, 2003) | |
| | DW | MITSUI et al., "A Novel Isoform of a Kallikrein-Like Protease, TLSP/Hippostasin, (PRSS20), IS Expressed in the Human Brain and Prostate", Biochem. Biophys. Res. Commun., 272:205-211 (May 27, 2000) | |
| | DX | OBIEZU et al., "Higher Human Kallikrein Gene 4 (KLK4) Expression Indicates Poor Prognosis of Ovarian Cancer Patients", Clin. Cancer Res., 7:2380-2386 (August, 2001) | |
| | DY | OZALP et al., "Effect of Cellular DNA Content on the Prognosis of Epithelial Ovarian Cancers", Gynecol. Obstet. Invest., 52:93-97 (2001) (Abstract) | |
| | DZ | PETRAKI et al., "Human Kallikrein 13 Expression in Normal Tissues: An Immunohistochemical Study", Histochem. Cytochem., 51(4):493-501 (April, 2003) | |
| | DDR | RIEGMAN et al., "Characterization of the Human Kallikrein Locus", Genomics, 14:6-11 (September, 1992) | |
| | DDS | RISCH, "Hormonal Etiology of Epithelial Ovarian Cancer, With a Hypothesis Concerning the Role of Androgens and Progesterone", J. Natl. Cancer Inst., 90:1774-1786 (December 2, 1998) | |
| ↓ | DDT | ROJO et al., "Expression and Clinical Significance of Pepsinogen C in Epithelial Ovarian Carcinomas", Eur. J. Obstet. Gynecol. Reprod. Biol., 104:58-63 (August 5, 2002) (Abstract) | |
| AMG | DDU | SAEDI et al., "Human Kallikrein 2 (HK2), But Not Prostate-Specific Antigen (PSA) Rapidly Complexes with Protease Inhibitor 6 (PT-6) Released from Prostate Carcinoma Cells", Int. J. Cancer, 94:558-563 (November, 2001) | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Anne Gussow/ | Date Considered | 03/07/2007 |
|--------------------|---------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

Sheet 8 of 9

Application Number 10/526,111
Filing Date November 22, 2005
First Named Inventor Yousef et al.
Art Unit 1643
Examiner Name A. Gussow
Attorney Docket Number MTS13AUSA**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. ¹ | Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| AMG | DDV | SAWIRIS et al., "Development of a Highly Specialized cDNA Array for the Study and Diagnosis of Epithelial Ovarian Cancer", Cancer Res., 62:2923-2928 (May 15, 2002) | |
| | DDW | SCHMALFELDT et al., Clin. "Increased Expression of a Matrix Metalloproteinases (MMP)-2, MMP-9, the Urokinase-Type Plasminogen Activator is Associated with Progression from Benign to Advanced Ovarian Cancer", Cancer Res., 7:2396-2404 (August, 2001) | |
| | DDX | SCHUMMER et al., "Comparative Hybridization of an Array of 21,500 Ovarian cDNAs for the Discovery of Genes Overexpressed in Ovarian Carcinomas", Gene, 238:375-389 (October 1, 1999) (Abstract) | |
| | DDY | SCORILAS, "Immunoenzymatically Determined Pepsinogen C Concentration in Breast Tumor Cytosols: An Independent Favorable Prognostic Factor in Node-Dependent Patients", Clin. Cancer Res. 5:1778-1785 (July, 1999) | |
| | DDZ | SCORILAS et al., "Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker", J. Clin. Oncol., 22(4):678 (February 15, 2004) | |
| | ER | SEETOO et al., "Quantitative Expression of Protein Markers of Plasminogen Activation System in Prognosis of Colorectal Cancer", J. Surg. Oncol. 82:184-193 (March, 2003) | |
| | ES | SHEN et al., "Prognostic Significance of Vascular Endothelial Growth Factor Expression in Human Ovarian Carcinoma", Br. J. Cancer, 83:196-203 (July, 2000) | |
| | ET | SHEVCHENKO et al., "Peptide Sequencing by Mass Spectrometry for Homology Searches and Cloning of Genes", J. Protein Chem., 16(5):481-490 (July, 1997) | |
| | EU | SOTIROPOULOU et al., "Emerging in the Kallikrein Gene Family for Understanding and Diagnosing Cancer", Oncol. Res. 13(6-10):381-391 (2003) (Abstract) | |
| | EV | STENMAN et al., "A Complex Between Prostate-Specific Antigen and α 1-Antichymotrypsin is the Major Form of Prostate-Specific Antigen in Serum of Patients with Prostatic Cancer: Assay of the Complex Improves Clinical Sensitivity for Cancer", Cancer Res., 51:222-226 (January 1, 1991) | |
| | EW | STEPHAN et al., "Molecular Forms of Prostate-Specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer", Cancer Epidemiol. Biomark. Prev., 9:1133-1147 (November, 2000) | |
| ✓ | EX | SUI et al., "Surviving Expression and its Correlation with Cell Proliferation and Prognosis in Epithelial Ovarian Tumors", Int. J. Oncol., 21:315-320 (August, 2002) | |
| AMG | EY | TAKAHASHI et al., "Down-Regulated Expression of Prostate-Specific Antigen in High-Grade or Hormone-Refractory Human Prostate Cancers", The Prostate, 54:187-193 (February 15, 2003) | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Anne Gussow/ | Date Considered | 03/07/2007 |
|--------------------|---------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Complete if Known

(Use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 9 | of | 9 |
|-------|---|----|---|

| | |
|------------------------|-------------------|
| Application Number | 10/526,111 |
| Filing Date | November 22, 2005 |
| First Named Inventor | Yousef et al. |
| Art Unit | 1643 |
| Examiner Name | A. Gussow |
| Attorney Docket Number | MTS13AUSA |

[illegible]

**Examiner
Signature**

/Anne Gussow/

Date
Considered

03/07/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.